High-dose therapy with stem cell support in solid tumors.
We describe some issues of ongoing studies and results in metastatic and high-risk breast cancer. Caution should be used to not over interpret the outcomes of these data given the patient selection. In other tumors with lesser developed studies, such as with ovarian cancer, non seminomatous germ cell tumors (NSGC), childhood sarcoma, melanoma and limited small cell carcinoma, promising outcomes in small phase II studies are identified and proposed or potential studies comparing high-dose therapy to conventional are outlined. High-dose therapy with either peripheral blood stem cell support (PBSC) or autologous bone marrow transplantation (ABMT) in Phase II studies on a diverse array of solid tumors shows exciting promise of long-term, disease-free survival. Comparative studies in early-stage patients are urgently needed to confirm these outcomes.
Division of Bone Marrow Transplantation, St. Louis University School of Medicine, Missouri 63110-0250.
G
G
Spitzer
F R
FR
Dunphy
C E
CE
Bowers
D R
DR
Adkins
D001943:Breast Neoplasms / Q000628:therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006412:Hematopoietic Stem Cells; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy; D012509:Sarcoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000628:therapy